At the 6th International Hospital Diabetes meeting, Glytec‘s eGlycemic Management System was featured in several studies demonstrating the products’s ability to save hospitals money.
One case study presented at the meeting described a health system that adopted Glytec’s eGlycemic Management System and saw 1st-year cost savings of $7.5 million.
The Kaweah Delta Medical Center attributed the savings to a 74% reduction in severe hypoglycemia and a 47% cut in point-of-care blood glucose testing. The Calif.-based medical center also experienced a 23% reduction in length of stay for patients who required insulin therapy.
Glytec’s eGMS, which combines an FDA-cleared insulin dosing system and integration with EMR and connected device systems, was used at the Kaweah Delta Medical Center from March 2016 until March this year.
“Hospital executives have a lot to contend with as they prepare their organizations for more value-based reimbursement. These presentations and studies again demonstrate why glycemic management truly merits prioritization when it comes to improving quality of care, patient safety, cost and value,” Raymie McFarland, Glytec’s VP of quality initiatives, said in prepared remarks. “There’s an abundance of compelling evidence surrounding the need for standardization and the value of adopting best practice. The case study presented by Rose Newsom of Kaweah Delta Medical Center is a great example of how employing a computerized, evidence-based systems approach with Glytec’s eGMS can result in an annualized cost savings of nearly $7.5 million for a single institution.”
Dr. Paul Chidester, VP of Medical Affairs at Sentara Norfolk General Hospital, also presented at the meeting and described Sentara Healthcare’s partnership with Glytec. He touted the safety and economic improvements that the 14-hospital health system has experienced since incorporating eGMS at all acute care facilities approximately 5 years ago. Chidester reportedly said that Sentara Healthcare plans to extend use of Glytec’s eGMS to its chronic care facilities later this year.
Finally, a 3rd study reported on the clinical benefits of Glytec’s eGMS. Dr. Marina Rabinovich of the Grady Memorial Hospital described how they’ve used the system for personalized insulin therapy among critically ill patients and claimed that they’ve experienced significant cuts in hypoglycemia.
The hospital’s study compared patients treated with conventional standards of care to those treated with eGMS and saw a 73% reduction in the number of patients who experienced severe hypoglycemia for the eGMS group versus the control arm. Rabinovich added that there was a 54% reduction in the number of patients who experienced mild hypoglycemia in the eGMS group compared to those who received standard care.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.